

Is Tau Approaching a Tipping Point in Alzheimer's Drug Development?

Is tau the new amyloid? Leaders in the Alzheimer's field have high conviction in tau — both as a target and surrogate endpoint — and they aren't letting a string of clinical misses deter them. Sound familiar? Yet tau stands apart from amyloid in key ways, including its closer relationship to symptoms and promise to avoid the worst side effects of anti-amyloid therapy. And this time, companies are armed with lessons learned from decades of designing clinical trials for the indication.

Read the entirety of the publication in its original format in *BIOCENTURY*, [here](#).